Skip to main content
. Author manuscript; available in PMC: 2015 Jun 8.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Jul 29;2(9):776ā€“781. doi: 10.1158/1940-6207.CAPR-09-0149

Fig. 2.

Fig. 2

HPV-16 status and OS in the TAX 324 trial. A, median OS by HPV status among all patients: 26.6 mo (95% CI, 19.9ā€“39.6) for HPV-negative (HPVāˆ’) patients versus not reached for HPV-positive (HPV+) patients (log-rank test P < 0.0001). B, median OS by HPV status among oropharyngeal patients: 19.7 mo (95% CI, 12.6ā€“34.9) for HPV-negative patients versus not reached for HPV-positive patients (log-rank test P < 0.0001). Fifty-nine of 68 patients with HPV-positive tumors had oropharyngeal cancer.